title: Molecular medicine: how, what, and when?
abstract: Integrating molecular medicine into clinical practice will create many challenges. But the existing genetic testing paradigm may not be the right model for introducing these new technologies.
authors.affiliation: Food and Drug Administration, Rockville, Maryland, USA. janet.woodcock@fda.hhs.gov
authors.forename: J
authors.initials: J
authors.lastname: Woodcock
mesh_terms: D015510:Clinical Medicine / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D019033:Delivery of Health Care, Integrated / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D005820:Genetic Testing / Q000191:economics / Q000331:legislation & jurisprudence; D033161:Government Regulation; D017408:Guidelines as Topic; D017048:Health Care Costs; D006291:Health Policy; D006301:Health Services Needs and Demand; D006302:Health Services Research; D006801:Humans; D008967:Molecular Biology / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D025202:Molecular Diagnostic Techniques / Q000191:economics; D018579:Patient Selection; D010597:Pharmacogenetics / Q000191:economics / Q000331:legislation & jurisprudence / Q000458:organization & administration*; D014481:United States